Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

Abstract The International Randomized Study of Interferon and STI571 (IRIS) demonstrated
long-term cytogenetic responses in patients with chronic-phase chronic myeloid leukemia …

Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if
treatment is withdrawn. We conducted a prospective clinical trial of imatinib withdrawal in 40 …

Background Imatinib treatment significantly improves survival in patients with chronic
myeloid leukaemia (CML), but little is known about whether treatment can safely be …

Recent evidence suggests chronic myeloid leukemia (CML) stem cells are insensitive to
kinase inhibitors and responsible for minimal residual disease in treated patients. We …

In less than 10 years, the prognosis of chronic myeloid leukaemia has changed from that of
a fatal disease to a disorder amenable simply to lifelong oral medication and compatible …

The success of tyrosine kinase inhibitors (TKIs) in treating chronic myeloid leukemia (CML)
depends on the requirement for BCR-ABL1 kinase activity in CML progenitors. However …

Abstract Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors has
advanced to a stage where many patients achieve very low or undetectable levels of …

Imatinib mesylate treatment markedly reduces the burden of leukemia cells in chronic
myelogenous leukemia (CML) patients. However, patients remain at risk for relapse on …

Abstract Around 40–50% of patients with chronic myeloid leukemia (CML) who achieve a
stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson …